Mark Angelino

Founder at Generation Bio Co.

Mark Angelino

Mark Angelino

Founder at Generation Bio Co.

Overview
Career Highlights

Generation Bio Co.

RelSci Relationships

1049

Number of Boards

1

Birthday

1973

Age

48

Relationships
RelSci Relationships are individuals Mark Angelino likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Disarm Therapeutics, Inc.

Relationship likelihood: Strong

President & Chief Executive Officer at Generation Bio Co.

Relationship likelihood: Strong

Founder at Generation Bio Co.

Relationship likelihood: Strong

Co-Founder at Rodin Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Translate Bio, Inc.

Relationship likelihood: Strong

Advisor at Atlas Venture, Inc.

Relationship likelihood: Strong

Chief Development Officer at Obsidian Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer at Nimbus Apollo, Inc.

Relationship likelihood: Strong

Senior Director, Neurology Research & Development at Biogen MA, Inc.

Relationship likelihood: Strong

Chief Financial Officer at Atlas Venture, Inc.

Relationship likelihood: Strong

Paths to Mark Angelino
Potential Connections via
Relationship Science
You
Mark Angelino
Founder at Generation Bio Co.
Education
PhD

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Founded by inventor, industrialist and philanthropist Peter Cooper in 1859, The Cooper Union for the Advancement of Science and Art offers an unparalleled education in art, architecture and engineering, and gives every admitted student a full-tuition scholarship. Believing that an education "equal to the best" should be accessible to those who qualify, independent of their race, religion, sex, wealth or social status, Peter Cooper, who himself had less than a year of formal schooling, established The Cooper Union to o?er a free education to working-class men and women without regard to gender, race, religion or economic status. A century and a half later, The Cooper Union is ranked among the ?nest American colleges. It remains a private institution with a public mission: To prepare gifted students to make enlightened contributions to the cultural and scienti?c life of our great urban centers

PhD

MIT Professional Education provides a gateway to MIT expertise and knowledge for science and engineering professionals around the world.

Career History
2008 - 2010

Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA.

Professional
Prior

Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. These innovative tools enable us to develop complex generics and follow-on biologics as well as facilitate the discovery of novel drugs. We believe that by applying our innovative technology to our discovery and development programs, we have the potential to create a robust pipeline of innovative generic and novel drugs. Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of both generic and novel complex mixture drugs designed to address a variety of medical needs. In July 2010, Momenta announced the FDA approval of our first drug, enoxaparin sodium injection developed in collaboration with Sandoz. Enoxaparin is a more affordable, generic version of Lovenox® (enoxaparin sodium injection), which is indicated for the prophylaxis of deep vein thrombosis (DVT). Enoxaparin sodium injection is a heparin-based complex mixture drug that was developed using our innovative scientific approach. Following this initial success, we are applying a similar approach to developing a generic version of Copaxone® (glatiramer acetate), a complex mixture of polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis. We are also adding follow-on biologics, which are highly similar and potentially interchangeable biologics, to our development pipeline. And finally, with the knowledge acquired from our complex generic and follow-on biologics business, we are our using our tools and technology to design and improve the structures of proteins and heparin-derived products to create novel drugs

Professional
Prior

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Boards & Committees
Director
2021 - Current

Arbor Biotechnologies, Inc. engages in curating genetic biodiversity and discover novel protein functions from nature. The company was founded by David Arthur Svott, Winston Xia Yan, Feng Zhang and David R. Walt in 2016 and is headquartered in Cambridge, MA.

Transactions
Details Hidden

Generation Bio Co. raised money in a private placement transaction

Details Hidden

Generation Bio Co. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Mark Angelino. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Mark Angelino's profile does not indicate a business or promotional relationship of any kind between RelSci and Mark Angelino.